VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.
VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+.
This is a Phase II/III clinical trial with two groups of adults successfully cured of category 1 pulmonary TB receiving either VPM1002 or placebo.
A single dose of VPM1002 or placebo will be administered to calculate the efficacy of the vaccine against TB recurrence.
Clinical Trial NCT03152903: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India